Correlation of Lymphocyte Count with Treatment Response to Tyrosine Kinase Inhibitors in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

被引：0
|
作者：
Sasaki, Koji [1 ]
Rodriguez-Rivera, Ildefonso Ismael [2 ]
Kantarjian, Hagop M. [1 ]
O'Brien, Susan [1 ]
Jabbour, Elias [1 ]
Borthakur, Gautam [1 ]
Ravandi, Farhad [1 ]
Burke, Michael J. [3 ]
Zweidler-McKay, Patrick A. [1 ]
Cortes, Jorge E. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Texas Southwestern, Austin, TX USA
[3] Med Coll Wisconsin, Milwaukee, WI 53226 USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Tyrosine Kinase Inhibitor Treatment for Newly Diagnosed Chronic Myeloid Leukemia
    Radich, Jerald P.
    Mauro, Michael J.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2017, 31 (04) : 577 - +
  • [2] Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A mixed-treatment comparison
    Firwana, Belal
    Sonbol, Mohamad Bassam
    Diab, Maria
    Raza, Shahzad
    Hasan, Rim
    Yousef, Ibrahim
    Zarzour, Ahmad
    Garipalli, Archana
    Doll, Donald
    Murad, M. Hassan
    Al-Kali, Aref
    INTERNATIONAL JOURNAL OF CANCER, 2016, 138 (06) : 1545 - 1553
  • [3] Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
    Tolomeo, Manlio
    Dieli, Francesco
    Gebbia, Nicola
    Simoni, Daniele
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2009, 9 (08) : 853 - 863
  • [4] THE LYMPHOCYTE DYNAMICS PREDICTS THE BETTER RESPONSE FOR DASATINIB TREATMENT IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE
    Najima, Y.
    Iriyama, N.
    Fujisawa, S.
    Yoshida, C.
    Wakita, H.
    Chiba, S.
    Okamoto, S.
    Kawakami, K.
    Takezako, N.
    Kumagai, T.
    Inokuchi, K.
    Ohyashiki, K.
    Taguchi, J.
    Yano, S.
    Igarashi, T.
    Kouzai, Y.
    Morita, S.
    Sakamoto, J.
    Sakamaki, H.
    HAEMATOLOGICA, 2015, 100 : 436 - 436
  • [5] Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A mixed-treatment comparison.
    Firwana, Belal
    Diab, Maria
    Sonbol, Mohamad Bassam
    Yousef, Ibraheem
    Hasan, Rim
    Raza, Shahzad
    Doll, Donald C.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] Second-Generation Tyrosine Kinase Inhibitors as First-Line Treatment Strategy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients
    Breccia, M.
    Alimena, G.
    CURRENT CANCER DRUG TARGETS, 2012, 12 (04) : 391 - 401
  • [7] Comparison of the Outcome between Newly Diagnosed Patients in the Accelerated Phase and Chronic Phase with Chronic Myeloid Leukemia Treated with Frontline Tyrosine Kinase Inhibitors
    Jiang, Qian
    Yu, Lu
    Qin, Ya-Zhen
    Lai, Yue-Yun
    Huang, Xiao-Jun
    BLOOD, 2017, 130
  • [8] Outcomes after Sequential Tyrosine Kinase Inhibitors Treatment in Chronic Phase Chronic Myeloid Leukemia
    Kong, Jee Hyun
    Winton, Elliott F.
    Heffner, Leonard
    Gaddh, Manila
    Hill, Brittany
    Arellano, Martha
    El-Rassi, Fuad
    Kim, Audrey
    Jillella, Anand
    Kota, Vamsi K.
    BLOOD, 2017, 130
  • [9] Outcomes of Chronic Phase Chronic Myeloid Leukemia after Treatment with Multiple Tyrosine Kinase Inhibitors
    Kong, Jee Hyun
    Winton, Elliott F.
    Heffner, Leonard T.
    Gaddh, Manila
    Hill, Brittany
    Neely, Jessica
    Hatcher, Angela
    Joseph, Meena
    Arellano, Martha
    El-Rassi, Fuad
    Kim, Audrey
    Khoury, Jean Hanna
    Kota, Vamsi K.
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (05)
  • [10] Phase II trials of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
    Ghanem, Hady
    Kantarjian, Hagop
    Cortes, Jorge
    Quintas-Cardama, Alfonso
    Jabbour, Elias
    EXPERT OPINION ON ORPHAN DRUGS, 2013, 1 (08): : 607 - 623
12345